Re:The press-release conviction of a biotech CEO and its imp...
by dalek_cannes on Thursday October 03, 2013 @01:01AM
(#6487277)
I initially thought he was partially justified in claiming the number with the 'mild-to-medium patients' qualification if there was a real benefit in the drug that the study had not been designed to detect. Except that a follow up study focusing on the mild-to-medium subgroup failed to show statistically significant benefits.
[ Parent
| on HN ]
There are no comments on this comment yet.